Nature Reviews Rheumatology - Table of Contents alert Volume 11 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2015 Volume 11 Number 2
Impact Factor 10.252 *	In this issue Research Highlights Year in Review Reviews Perspectives Correspondence Also this month  Featured article: Exercise as an anti-inflammatory therapy for rheumatic diseases—myokine regulation Fabiana B. Benatti & Bente K. Pedersen
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Communications is now fully open access All new submissions to Nature Communications, if accepted, will be published open access and an article processing charge will apply. For more information visit the website. Many research funders and institutions make funds available to pay open access APCs: please consult our open access funding page to check if your funder or institution has funding available. For advice on whether you are eligible for APC funding and help in approaching funders and institutions please contact us at openaccess@nature.com.
RESEARCH HIGHLIGHTS Top Connective tissue diseases: Adipocyte-myofibroblast transition: linking intradermal fat loss to skin fibrosis in SSc Published online: 06 January 2015 p63 | doi:10.1038/nrrheum.2014.223 PDF Rheumatoid arthritis: Inflammation feeds inflammation—HDAC5 downregulation leads to activation of fibroblast-like synoviocytes in RA Published online: 16 December 2014 p64 | doi:10.1038/nrrheum.2014.213 PDF Osteoarthritis: MicroRNA-mediated meniscal injury repair in rats Published online: 16 December 2014 p64 | doi:10.1038/nrrheum.2014.214 PDF
YEAR IN REVIEW		Top
Osteoarthritis in 2014: Changing how we define and treat patients with OA Rebecca F. Moyer & David J. Hunter Published online: 16 December 2014 p65 | doi:10.1038/nrrheum.2014.211 Important advances in 2014 foster new perspectives on definitions of early and end-stage disease, and promote a shift in the clinical management of osteoarthritis (OA) through implementing treatment algorithms intended to minimize strain on current health-care models. Collectively, these changes shed new light on developing and optimizing approaches to OA treatment. Full Text | PDF
Clinical genetics in 2014: New monogenic diseases span the immunological disease continuum Sinisa Savic & Michael F. McDermott Published online: 23 December 2014 p67 | doi:10.1038/nrrheum.2014.215 Three monogenic diseases, with features of both autoinflammation and autoimmunity, were described for the first time in 2014. As well as providing insights into the molecular basis of several rare immunological disorders, the discoveries have implications for their diagnosis and treatment. Full Text | PDF
Rheumatoid arthritis in 2014: Exciting times for RA research Paul Emery Published online: 23 December 2014 p69 | doi:10.1038/nrrheum.2014.216 2014 saw the emergence of a novel rheumatoid arthritis therapy to rival methotrexate, as well as advances in our understanding of mouse T-cell biology and of the cross-talk between the nervous system and the immune system. How will these advances affect the future of rheumatoid arthritis research and therapy? Full Text | PDF
Paediatric rheumatology in 2014: Digging deeper for greater precision and more impact in JIA Berent Prakken & Alberto Martini Published online: 06 January 2015 p70 | doi:10.1038/nrrheum.2014.224 Optimizing the management of childhood arthritis requires detailed knowledge of the disease in an individual patient. Advances in 2014 show how in-depth genetic studies and insights into immunopathogenesis could translate into clinical biomarkers and, eventually, individualized therapy. Full Text | PDF
Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design Yannick Allanore & Oliver Distler Published online: 06 January 2015 p72 | doi:10.1038/nrrheum.2014.222 The treatment and study of systemic sclerosis (SSc) is entering a new era with the reporting and preparation of several randomized controlled trials according to an improved understanding of SSc pathogenesis. Advances in trial designs reported in 2014 should now be built upon with further improvements to patient selection to enable targeting of therapies to specific subgroups of patients with SSc. Full Text | PDF
Osteoimmunology in 2014: Two-faced immunology—from osteogenesis to bone resorption Hiroshi Takayanagi Published online: 06 January 2015 p74 | doi:10.1038/nrrheum.2014.219 Even though activation of immunity is associated with bone destruction, new mechanisms have been described in 2014 through which immunology-associated pathways can cooperate to support osteogenesis. These advances support the view of the immune system as a central mechanism which can regulate bone homeostasis, regeneration and destruction. Full Text | PDF
REVIEWS		Top
Advances in arthroscopy—indications and therapeutic applications Andrew J. Carr, Andrew J. Price, Sion Glyn-Jones & Jonathan L. Rees Published online: 28 October 2014 p77 | doi:10.1038/nrrheum.2014.174 In comparison with traditional surgery techniques, arthroscopic surgeries induce less tissue damage and can reduce morbidity and complications. In this Review, Carr and colleagues focus on the increased use of therapeutic arthroscopy as a tool for excision, reconstruction and replacement of damaged or abnormal tissue, and signal the need for additional studies to allow this surgical approach to reach its full potential. Abstract | Full Text | PDF
Exercise as an anti-inflammatory therapy for rheumatic diseases—myokine regulation Fabiana B. Benatti & Bente K. Pedersen Published online: 25 November 2014 p86 | doi:10.1038/nrrheum.2014.193 Contrary to earlier beliefs, evidence now exists that exercise does not exacerbate systemic inflammatory diseases, such as rheumatoid arthritis. In this Review of exercise therapy for rheumatic diseases, the authors propose that, by interrupting a cycle of local inflammation, obesity, metabolic dysregulation and systemic inflammation, exercise is medicine. Abstract | Full Text | PDF
Glucocorticoid-induced osteoporosis: who to treat with what agent? René Rizzoli & Emmanuel Biver Published online: 11 November 2014 p98 | doi:10.1038/nrrheum.2014.188 Glucocorticoid therapy is associated with bone loss and increased risk of fracture, but these deleterious effects can be avoided or mitigated with appropriate treatment. When to initiate anti-osteoporosis therapy and what form this preventive therapy should take is the focus of this Review. Abstract | Full Text | PDF
The changing clinical picture and epidemiology of spondyloarthritis Astrid van Tubergen Published online: 11 November 2014 p110 | doi:10.1038/nrrheum.2014.181 The ASAS classification criteria for axial and peripheral subgroups are beginning to alter our understanding of spondyloarthritis. In this article, Astrid van Tubergen discusses how these criteria are changing not only our clinical understanding, but also the epidemiology, including prevalence and incidence calculations. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Sorting out the risks in progressive multifocal leukoencephalopathy Leonard H. Calabrese, Eamonn Molloy & Joseph Berger Published online: 14 October 2014 p119 | doi:10.1038/nrrheum.2014.167 Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the central nervous system that is associated with several immunosuppressive therapies. In this Opinion article, Calabrese and colleagues propose a ranking of immunosuppressive agents based on their risk of PML to support a better-informed decision-making process. Abstract | Full Text | PDF
CORRESPONDENCE		Top
High-resolution peripheral quantitative CT in rheumatology Cheryl Barnabe, Stephanie Finzel, Kathryn S. Stok & Piet Geusens Published online: 20 January 2015 p123 | doi:10.1038/nrrheum.2014.145-c1 Full Text | PDF
Reply: HR-pQCT has promise in rheumatology Emilio Filippucci, Luca Di Geso & Walter Grassi Published online: 20 January 2015 p123 | doi:10.1038/nrrheum.2014.145-c2 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.